Renovorx - FloodGate Medical

Delivering Therapy Where it Matters

About Us

RenovoRx is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted drug-delivery offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

Look at the Leaders of RenovoRX

Shaun R. Bagai

Chief Executive Officer

Ramtin Agah

Chief Medical Officer, Founder

Mark Voll

Chief Financial Officer

Our Therapy Platform

Trans-Arterial Micro-perfusion (TAMP™) is an Innovative Therapy Platform Designed for Localized and Targeted Delivery of Existing and Novel Oncology Agents to Tumors

Our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. TAMP is enabled by our patented, FDA-cleared RenovoCath^® device. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx’s novel approach to targeted treatment offers patients with solid tumor cancers the potential for increased safety, tolerance, and improved efficacy.

In addition to the RenovoCath device, we are also evaluating our novel combination oncology product candidate, IAG, which utilizes RenovoCath. The combination oncology product candidate is currently being evaluated for the treatment of LAPC under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. The combination product candidate, enabled the RenovoCath device, is currently under investigation and has not been approved for commercial sale.

Localized and Targeted Therapy

TAMP is specifically designed for the localized and targeted delivery of chemotherapy via the peripheral vascular system. TAMP begins with standard artery access, where the RenovoCath device is inserted through the blood vessels to target the tumor. RenovoCath’s double balloon design enables the physician to isolate sections of the blood vessel through the adjustment of the distance between the balloons, thereby excluding any side branches in order to create the pressure head needed to push chemotherapy across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.

Targeted Delivery In Action

The first of two interim analyses was completed in March 2023, and the DMC recommended a continuation of the study. The study is prespecified to provide a primary endpoint of a 6-month OS benefit and secondary endpoints including reduced side effects versus standard of care.

Company Spotlight Video

Pipeline Overview

Committed to Transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care.

While the oncology field has made progress with the treatment of cancers over the past few decades, the limited effectiveness of chemotherapy accompanied by debilitating side effects remains a barrier to standard of care treatment. The common objective in chemotherapy treatment innovation is to enhance dosing of the drug, while minimizing systemic toxicity. The standard of care for most cancers is systemic (intravenous) chemotherapy, which delivers chemotherapy throughout the body.

Our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. TAMP is enabled by our patented, FDA-cleared RenovoCath device. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!